Skip to main content
. 2003 May 19;197(10):1323–1334. doi: 10.1084/jem.20021952

Figure 6.

Figure 6.

Requirement of Bax and/or Bak for NFX*- or CPX-induced cell death. (A) SV40-transformed WT MEF or Bax−/− Bak−/− DKO cells were exposed to NFX* and CPX for the indicated period, followed by determination of the frequency of DiOC6(3)low and annexin V–positive cells. (B) MEF lacking Bax, Bak, Bax and Bak (DKO), or Bid were exposed to either NFX* or CPX and the indicated parameters were measured. (C) NFX*- and CPX-induced cathepsin B release in control and Bax−/− Bak−/− DKO cells, as determined by immunostaining. The percentage of cells exhibiting diffuse cathepsin B staining as well as those with diffuse cytochrome c staining has been quantified. (D) Failure of chemical cathepsin inhibition to prevent NFX*- or CPX-induced cell death. HeLa cells were pretreated with the indicated cathepsin inhibitors, followed by determination of the frequency of DiOC6(3)low and PIhigh cells. (E) Cathepsins are dispensable for NFX*- or CPX-induced cell death. MEF with the indicated genotypes were treated with NFX* or CPX, and apoptotic parameters were measured as in D. Results are means ± SD of three independent determinations.